Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services rendered. This approach incentivizes proactive care, chronic disease management and overall cost efficiency.
High-performing healthcare organizations that successfully implement value-based care are seeing not only improved patient outcomes but also increased financial performance. Organizations that excel in value-based care realize revenue growth through:
Healthcare systems that fail to adapt risk being left behind as government and private payers continue shifting toward value-based care models. But all of this requires an increased and efficient handle on data, providing more effective patient care and comprehensive cost control.
Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is helping providers streamline their transition to value-based care. Through its ProActive Care Platform, Adageis enables healthcare organizations to optimize patient care while maximizing financial performance (https://ibn.fm/Y5C6O).
Adageis’ solutions integrate directly with existing electronic health record (“EHR”) systems, ensuring a seamless transition without disrupting workflows. Its key features include:
By leveraging advanced analytics and machine learning, Adageis enables providers to shift from reactive to proactive care—essential for success in a value-based care environment.
Additionally, one of the biggest challenges in value-based care is accurately measuring and improving patient outcomes. Adageis addresses this by offering real-time data insights that help providers identify gaps in care and address them proactively, track patient engagement and adherence to treatment plans, predict health trends to optimize resource allocation, and benchmark performance against value-based care reimbursement models.
As the healthcare industry continues its shift toward value-based care, the organizations that embrace technology-driven solutions will have a competitive edge. AI-powered tools, like those developed by Adageis, will play a central role in improving care quality, enhancing efficiency and driving financial growth.
For more information, visit the company’s website at www.Adageis.com.
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
The global market for brain tumor treatments is experiencing significant transformation powered by advances in…
A team of researchers has developed a “cost-effective” and simple blood test with the potential…
Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…
Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…
Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…
Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…